Australia’s Specialized Therapeutics has entered a sublicense agreement enabling the local subsidiary of Mundipharma International to assume all commercialization responsibilities for the anti-emetic products Aloxi (palonosetron hydrochloride) and Akynzeo (netupitant/palonosetron).
Under the terms of the arrangement, Specialized Therapeutics grants Mundipharma exclusive marketing, promotion, distribution and sales rights for these two anti-nausea and vomiting pharmaceutical products in Australia and New Zealand markets.
Aloxi is indicated for the prevention of acute nausea and vomiting associated with chemotherapy and has been commercially available in Australia since 2010 under license from Swiss drugmaker Helsinn Healthcare, which has consented to the sublicense agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze